


Shanghai Genchem announces global collaboration with I-Mab on Bispecific antibodies

06 April 2021 | News

Aims to develop and commercialize multiple bi-specific antibodies (BsAb) based on monoclonal antibody



Shanghai Genechem Co., Ltd., a discovery company dedicated to novel drug target discovery and development of novel therapeutics, announced the execution of a global collaboration with I-Mab, a Nasdaq-listed global biopharmaceutical company, to develop and commercialize multiple bi-specific antibodies (BsAb) based on monoclonal antibody developed by Genechem and antibodies selected by I-MAB.

"This collaboration is the first of many that will leverage Genechem's Good Research Practice (GRP) and CHAMP antibody discovery platform, strong bioinformatic database, as well as strong development expertise of synergistic partners, to deliver globally competitive assets based on innovative targets. We are excited to collaborate with I-Mab, a global leader in Oncology and antibody development, to bring more products to address clinical unmet needs for patients inChina and globally", commented Yueqiong Cao, Founder and CEO of Genechem.